Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease
Authors' conclusion
In adults with T2D and ASCVD, OW GLP-1 RAs are associated with reduced stroke and MI risks and ASCVD-related and all-cause HCRU and costs vs DPP-4is.
Study context
- Population
- New adult users of once-weekly (OW) GLP-1 RAs or DPP-4is with T2D and atherosclerotic cardiovascular disease (ASCVD), Optum Clinformatics Data Mart, 1/1/2017–9/30/2021weighted cohorts
- Exposure
- OW GLP-1 RAs vs DPP-4is
- Outcome
- Time to ischemic stroke, MI, or their composite
- Follow-up
- During exposure
Methodological detailsobservational, inverse probability of treatment weighting, new-user design, Baseline characteristics balanced using inverse probability of treatment weighting; survival analyses compared risks during exposure
- Observational
- Inverse probability of treatment weighting
- New-user design
- Baseline characteristics balanced using inverse probability of treatment weighting; survival analyses compared risks during exposure
Main finding
As reported in the abstract
Ischemic stroke, MI and composite
Lower risk of ischemic stroke with OW GLP-1 RA vs DPP-4i (P < 0.01)
26%
Lower risk of myocardial infarction (MI) with OW GLP-1 RA vs DPP-4i (P < 0.01)
22%
Lower risk of composite of ischemic stroke and MI with OW GLP-1 RA vs DPP-4i (P < 0.01)
24%
Observational data: associations, not effects.
Further findings
Health care resource utilization (HCRU) and medical costs
- Lower ASCVD-related hospitalization costs with OW GLP-1 RA vs DPP-4i (P < 0.01)
- 25%
- Lower all-cause hospitalization costs (P < 0.01)
- 26%
- Lower ASCVD-related medical costs (P < 0.01)
- 19%
- Lower all-cause medical costs (P < 0.01)
- 23%
- Fewer ASCVD-related hospitalizations (P < 0.01)
- 23%
- Fewer all-cause hospitalizations (P < 0.01)
- 27%
- Fewer ASCVD-related outpatient visits (P < 0.01)
- 13%
- Fewer all-cause outpatient visits (P < 0.01)
- 8%
- Fewer all-cause ER visits (P < 0.01)
- 8%
Original publication
Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease. Cardiovasc Diabetol. Published 20 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →